Table 1.
Patients’ characteristics (N = 285)
| Patients’ characteristics | N(%) |
|---|---|
| Age | |
| Median | 57 |
| Range | 24–87 |
| Sex | |
| Male | 210 (73.7) |
| Female | 75 (26.3) |
| T Stage | |
| T1-2 | 28 (9.8) |
| T3-4 | 257 (90.2) |
| N Stage | |
| Negative | 11 (3.9) |
| Positive | 274 (96.1) |
| Metastasis | |
| Negative | 260 (91.2) |
| Positive | 25 (8.8) |
| Radiotherapy | |
| 45 Gy (25 Fx in 5 weeks) | 251 (88.1) |
| 50.4 Gy (28 Fx in 5.5 weeks) | 20 (7.0) |
| Others | 14 (4.9) |
| Chemotherapy regimen | |
| No concurrent chemo | 31 (10.9) |
| Capecitabine | 61 (21.4) |
| S-1 | 173 (60.7) |
| Others (XELOX; SOX; FOLFIRI) | 20 (7.0) |
| Treatment type | |
| Neoadjuvant | 67 (23.5) |
| Adjuvant | 189 (66.3) |
| Palliative | 29 (10.2) |
FOLFIRI: Irinotecan + 5-Fu; SOX: Oxaliplatin + Tegafur;XELOX: Oxaliplatin + Capecitabine.